Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo

Key PointsAbbVie’s ABBV-466 nearly doubled Skyrizi’s Crohn’s remission rate in a Phase 2 study.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Monday 2 November →